J G Storosum

Summary

Affiliation: Medicines Evaluation Board of the Netherlands
Country: The Netherlands

Publications

  1. ncbi Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Den Haag
    Pharmacopsychiatry 37:32-6. 2004
  2. ncbi Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, P O Box 16229, 2500 BE, Den Haag, The Netherlands
    Eur Neuropsychopharmacol 11:173-80. 2001
  3. ncbi Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, PO Box 16229, 2500 BE Den Haag, The Netherlands
    Am J Psychiatry 162:799-802. 2005
  4. ncbi How real are patients in placebo-controlled studies of acute manic episode?
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, PO Box 16229, 2500 BE Den Haag, The Netherlands
    Eur Neuropsychopharmacol 14:319-23. 2004
  5. ncbi Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, The Hague, The Netherlands
    Bipolar Disord 9:793-8. 2007
  6. ncbi Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Den Haag, The Netherlands
    Arch Gen Psychiatry 60:365-8. 2003
  7. ncbi Suicide risk in placebo-controlled studies of major depression
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, 2500 BE Den Haag, The Netherlands
    Am J Psychiatry 158:1271-5. 2001
  8. ncbi Antidepressants use in children and adolescents and the risk of suicide
    Tamar D Wohlfarth
    Medicenes Evaluation Board of the Netherlands, The Hague
    Eur Neuropsychopharmacol 16:79-83. 2006
  9. ncbi Response to tricyclic antidepressants: independent of gender?
    Tamar Wohlfarth
    Medicines Evaluation Board of the Netherlands, Den Haag, The Netherlands
    Am J Psychiatry 161:370-2. 2004
  10. ncbi Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues
    J G Storosum
    Medicines Evaluation Board of the Netherlands Den Haag, The Hague, The Netherlands
    Eur Psychiatry 16:327-35. 2001

Collaborators

  • Tamar D Wohlfarth
  • Wim van den Brink
  • Arif Khan
  • Lonneke J M van Nimwegen
  • Hiske Becker
  • Therese Van Amelsvoort
  • Eric Fliers
  • Henk W Venema
  • Regje M E Blumer
  • Gideon Allick
  • Lieuwe De Haan
  • Hans P Sauerwein
  • Mireille J M Serlie
  • Mariette T Ackermans

Detail Information

Publications12

  1. ncbi Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Den Haag
    Pharmacopsychiatry 37:32-6. 2004
    ..This study was conducted to investigate the role of natural course of a major depressive episode in short-term, placebo-controlled studies...
  2. ncbi Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, P O Box 16229, 2500 BE, Den Haag, The Netherlands
    Eur Neuropsychopharmacol 11:173-80. 2001
    ..Therefore in major depression, placebo-controlled studies are still necessary to demonstrate efficacy...
  3. ncbi Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, PO Box 16229, 2500 BE Den Haag, The Netherlands
    Am J Psychiatry 162:799-802. 2005
    ..If so, this would be a strong ethical argument against the conduct of such studies...
  4. ncbi How real are patients in placebo-controlled studies of acute manic episode?
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, PO Box 16229, 2500 BE Den Haag, The Netherlands
    Eur Neuropsychopharmacol 14:319-23. 2004
    ..To determine whether the results from placebo-controlled studies conducted in patients with manic episode can be generalised to a routine population of hospitalised acute manic patients...
  5. ncbi Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, The Hague, The Netherlands
    Bipolar Disord 9:793-8. 2007
    ..To provide an accurate estimation of the magnitude of effect of lithium in short-term efficacy studies conducted in patients with moderate to severe manic episode...
  6. ncbi Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Den Haag, The Netherlands
    Arch Gen Psychiatry 60:365-8. 2003
    ..We tested whether the risk of suicide and attempted suicide in the placebo arms of placebo-controlled studies among patients with schizophrenia is higher than in the active treatment arms of such studies...
  7. ncbi Suicide risk in placebo-controlled studies of major depression
    J G Storosum
    Medicines Evaluation Board of the Netherlands, Kalvermarkt 53, 2500 BE Den Haag, The Netherlands
    Am J Psychiatry 158:1271-5. 2001
    ....
  8. ncbi Antidepressants use in children and adolescents and the risk of suicide
    Tamar D Wohlfarth
    Medicenes Evaluation Board of the Netherlands, The Hague
    Eur Neuropsychopharmacol 16:79-83. 2006
    ..Antidepressants use in paediatric patients has been linked with risk of suicidal behaviours. The aim of this paper, therefore, is to examine whether all antidepressants are associated with such risk...
  9. ncbi Response to tricyclic antidepressants: independent of gender?
    Tamar Wohlfarth
    Medicines Evaluation Board of the Netherlands, Den Haag, The Netherlands
    Am J Psychiatry 161:370-2. 2004
    ..The authors examined gender differences in response to tricyclic antidepressants...
  10. ncbi Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues
    J G Storosum
    Medicines Evaluation Board of the Netherlands Den Haag, The Hague, The Netherlands
    Eur Psychiatry 16:327-35. 2001
    ..g., HDRS < 7) as a possible option...
  11. ncbi Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?
    Jitschak G Storosum
    Medicines Evaluation Board of the Netherlands, Den Haag, The Netherlands
    Schizophr Bull 28:193-201. 2002
    ..Probably amisulpride is efficacious on these nonenduring primary negative symptoms...
  12. ncbi Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism
    Lonneke J M van Nimwegen
    Department of Psychiatry, Adolescent Clinic, Laboratory of Endocrinology and Radiochemistry, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands
    J Clin Endocrinol Metab 93:572-7. 2008
    ..Our objective was to measure insulin sensitivity and body composition in antipsychotic-naive patients with DSM IV schizophrenia and/or schizoaffective disorder compared with matched controls...